Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.

Sousa LF, Coelho FM, Rodrigues DH, Campos AC, Barcelos Lda S, Teixeira MM, Rachid MA, Teixeira AL.

Clinics (Sao Paulo). 2013;68(3):391-4.

2.

Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.

Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.

Eur Cytokine Netw. 2006 Mar;17(1):35-41.

3.

The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.

Coelho FM, Pinho V, Amaral FA, Sachs D, Costa VV, Rodrigues DH, Vieira AT, Silva TA, Souza DG, Bertini R, Teixeira AL, Teixeira MM.

Arthritis Rheum. 2008 Aug;58(8):2329-37. doi: 10.1002/art.23622.

4.
5.

Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia.

Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A, Mennini T, Ghezzi P, Villa P.

Cytokine. 2005 May 7;30(3):125-31.

PMID:
15826819
6.

C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent.

Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, Fusco DJ, Hickman ZL, Kim GH, Komotar RJ, Mocco J, Connolly ES.

J Cereb Blood Flow Metab. 2008 May;28(5):1048-58. doi: 10.1038/sj.jcbfm.9600608. Epub 2008 Jan 16.

PMID:
18197178
7.

The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats.

Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S, Bigini P, Mennini T, Gelosa P, Tremoli E, Sironi L, Ghezzi P.

Mol Med. 2007 Mar-Apr;13(3-4):125-33.

8.

A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.

Opfermann P, Derhaschnig U, Felli A, Wenisch J, Santer D, Zuckermann A, Dworschak M, Jilma B, Steinlechner B.

Clin Exp Immunol. 2015 Apr;180(1):131-42. doi: 10.1111/cei.12488.

9.

CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.

Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L.

Diabetes. 2015 Apr;64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14.

10.

CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L, Ruffini PA, Allegretti M, Secchi A, Bonifacio E, Piemonti L.

J Clin Invest. 2012 Oct;122(10):3647-51. doi: 10.1172/JCI63089. Epub 2012 Sep 17.

11.

Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.

Cunha TM, Barsante MM, Guerrero AT, Verri WA Jr, Ferreira SH, Coelho FM, Bertini R, Di Giacinto C, Allegretti M, Cunha FQ, Teixeira MM.

Br J Pharmacol. 2008 May;154(2):460-70. doi: 10.1038/bjp.2008.94. Epub 2008 Mar 24.

12.

CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia.

Choe CU, Lardong K, Gelderblom M, Ludewig P, Leypoldt F, Koch-Nolte F, Gerloff C, Magnus T.

PLoS One. 2011;6(5):e19046. doi: 10.1371/journal.pone.0019046. Epub 2011 May 13. Erratum in: PLoS One. 2011;6(7). doi:10.1371/annotation/295c388d-013d-4bb9-b4e4-da8e88317594.

13.

Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats.

Chauhan A, Sharma U, Jagannathan NR, Reeta KH, Gupta YK.

Behav Brain Res. 2011 Dec 1;225(2):603-9. doi: 10.1016/j.bbr.2011.08.035. Epub 2011 Aug 31. Erratum in: Behav Brain Res. 2012 Apr 15;229(2):451.

PMID:
21903138
14.

In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.

Petty MA, Neumann-Haefelin C, Kalisch J, Sarhan S, Wettstein JG, Juretschke HP.

Eur J Pharmacol. 2003 Aug 1;474(1):53-62.

PMID:
12909195
15.

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.

Bertini R, Barcelos LS, Beccari AR, Cavalieri B, Moriconi A, Bizzarri C, Di Benedetto P, Di Giacinto C, Gloaguen I, Galliera E, Corsi MM, Russo RC, Andrade SP, Cesta MC, Nano G, Aramini A, Cutrin JC, Locati M, Allegretti M, Teixeira MM.

Br J Pharmacol. 2012 Jan;165(2):436-54. doi: 10.1111/j.1476-5381.2011.01566.x.

16.

A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.

Vieira SM, Lemos HP, Grespan R, Napimoga MH, Dal-Secco D, Freitas A, Cunha TM, Verri WA Jr, Souza-Junior DA, Jamur MC, Fernandes KS, Oliver C, Silva JS, Teixeira MM, Cunha FQ.

Br J Pharmacol. 2009 Oct;158(3):779-89. doi: 10.1111/j.1476-5381.2009.00367.x. Epub 2009 Aug 20.

18.

Cocaine-and amphetamine-regulated transcript modulates peripheral immunity and protects against brain injury in experimental stroke.

Chang L, Chen Y, Li J, Liu Z, Wang Z, Chen J, Cao W, Xu Y.

Brain Behav Immun. 2011 Feb;25(2):260-9. doi: 10.1016/j.bbi.2010.09.017. Epub 2010 Sep 30.

PMID:
20869431
19.

ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke.

Connell BJ, Gordon JR, Saleh TM.

Neurosci Lett. 2015 Oct 8;606:117-22. doi: 10.1016/j.neulet.2015.08.041. Epub 2015 Aug 28.

PMID:
26320021
20.

Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV.

Circulation. 2001 Apr 3;103(13):1799-805.

Supplemental Content

Support Center